1. A paradigm shift in the skincare industry
Sean Shelby
TELEOST
Biopharmaceutical
2. Imagine a transformational patch, with the same effect of tanning as achieved in
a booth or through sunbathing, which gives photoprotection from within the
body. Tan in the dark. Safe from UVB and UVA irradiation completely opposite
from sunscreen applications. Our cosmeceutical peptides naturally stimulate the
skin’s innate tanning pathway. We plan to use the strategy applied to teeth
whitening: appeal to vanity. This revolutionary product will change the skincare
market in ways never seen before.
1
3. 2
We have an opportunity with a
basis for a high value mass-
market that will make tanning
beds and sprays a thing of the
past. Our molecules are derived
from gamma MSH and are
highly selective for the MC1
receptor which targets primarily
pigmentation of the skin. This is
a new discovery at the
University of Arizona.
opportunity
4. 3
Teleost technology could boost skin
levels 2-3 types in 3-5 days after
application lasting for 30-45 days.
5. The initial markets we will
approach are skin care, tanning,
anti-wrinkle, and anti-aging. The
peptides we have developed can be
administered topically as
ingredients in creams, lotions, or
through a transdermal patch. The
primary target is to stimulate the
body’s built-in photoprotective
process. Our products will not
require UV radiation (sun or booth
sources). Our products provide an
increase in UV protection without
the need for chemical substitutes.
4
6. • Mission – Help people protect themselves
from harsh UV rays of the sun by
stimulating natural healthy melanin
production
• Objective – Develop products that reduce
dermatological illnesses by stimulating
natural pigment processes
• Origin - Based on extensive research by
Prof. Victor Hruby, UA, on Gamma-
Melanocyte Stimulating Hormone (γ-
MSH) 5
What is Teleost Biopharmaceuticals?
g-MSH is a naturally
occurring peptide
hormone which is released
by skin cells in response
to the stimulation by
ultraviolet radiation.
7. What’s the Problem?
● Each year nearly 5 million people are treated for skin
cancer in the US.
● Each year there are more new cases of skin cancer
than the combined incidence of cancers of the breast,
prostate, lung and colon.
● Over the past three decades, more people have had
skin cancer than other cancers combined.
● One in five Americans will develop skin cancer in their
lifetime.
● One person dies from melanoma every hour.
6
8. Our Solution
● Cosmeceutical route will enable people to develop a first line
of defense against skin maladies.
● Our product is safe for children.
● Our will not only change how we can but help millions of
protect themselves.
● Appeals to growing popularity of multifunctional benefits in a
single product.
7
9. Production
• IP
- Peptides that stimulate natural melanin
production from within for healthy self
tanning
• Current state of IP
- Exclusive License from University of
Arizona
• Current State of Product
- Proof of concept phase for topically
applied synthetic-peptides
8
10. • More specific to individuals
• Fewer side effects
• It is transformational!
- UV is not needed (No sunlight, tanning bed or spray
tan)
- Use ANY time of year to darken skin
- Apply once a month to have a sustained skin color
(based on research studies)
- No needles to apply
- A preventative measure to fight against cancer spread
● We want to naturally make people’s skin darker to keep
them safe 9
How are we different?
11. Market
Focus - Dermatology
1. Cosmetics - $5B
- Tanning Lotions
- Wrinkle prevention
- Moisturizers
- Anti-Aging
2. Nutritional Supplement
- no use of harming sun
- no tanning beds or spray tan
- all natural melanin production
3. Cancer Prevention
- the darker your skin the less of a chance you
will get skin cancer
• Aging population
• Non-surgical youthful
appearance
• Demand for science-oriented
premium cosmetics
• Demand for environment
friendly products
• Per capita disposable income
10
12. The Competition
Clinuvel:
● Licensed similar technology 10 years ago.
● Their molecule is less selective and has more affinity
towards other MCR 3,4,5 which leads to side effects.
● These side effects are a problem for mass usage.
● Currently requires subcutaneous injection and has no
nutra or cosmeceutical lines developed.
11
13. Marketing Schedule
Future
● Expand Applications
● Use Market Participants
● Continue IP Development
● Reserve rights for
Diagnostics & Pharma
drugs
Now
● Identify Potential
Partners
● Leverage Inventor
● Build Acceptance
12
14. Team
Advisors
- Dr. Victor Hruby, PhD (Chief Scientific Advisor, Co-inventor)
- Dr. Minying Cai, PhD (Chief Research Advisor, Co-inventor)
- Lawrence Hecker (Corporate Attorney)
- Quan Nguyen (Patent Attorney)
- Dr. Peter Cogen, PhD (Drug Design & Delivery Advisor)
13
Sean Shelby:
CEO, Co-inventor of critical peptide family
